TapewireFind a company

person · Reporting owner

Dreyer Scott

Disclosed activity across 1 company

Tapewire entity
62525
SEC CIK
0001746251

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169EVP & Chief Commercial OfficerMarch 03, 2026March 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COLLEGIUM PHARMACEUTICAL, INC

Report date March 03, 2026 · Filed March 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect71,770 Ending reported balance After 2026-03-03 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-03-03 · Sale · Disposed 46,417 · Balance 75,329

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.835 to $40.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Row 2 · 2026-03-03 · Sale · Disposed 3,559 · Balance 71,770

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.84 to $41.35, inclusive.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.835 to $40.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.84 to $41.35, inclusive.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 03, 2026 Filed Mar 5, 2026 21:29 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 3,559 $40.99 $145,879.50
Disclosure

SEC source: 0001746251-26-000004 · form4-03052026_090346.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,770

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.84 to $41.35, inclusive.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:29 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 46,417 $40.36 $1,873,557.22
Disclosure

SEC source: 0001746251-26-000004 · form4-03052026_090346.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,329

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.835 to $40.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:30 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 21,615 $46.75 $1,010,501.25
Disclosure

SEC source: 0001746251-26-000002 · form4-02122026_040201.xml · nonDerivative · entry 4

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,746

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:30 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 9,977 $46.75 $466,424.75
Disclosure

SEC source: 0001746251-26-000002 · form4-02122026_040201.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,361

F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:30 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 30,702 $0.00 $0.00
Disclosure

SEC source: 0001746251-26-000002 · form4-02122026_040201.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,338

F2 · shares: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 30,702 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Read SEC document
February 10, 2026 Filed Feb 12, 2026 21:30 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 19,023 $0.00 $0.00
Disclosure

SEC source: 0001746251-26-000002 · form4-02122026_040201.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,636

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
December 08, 2025 Filed Dec 10, 2025 21:32 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 17,600 $0.00 Strike: $15.90 $0.00
Disclosure

SEC source: 0001746251-25-000004 · form4-12102025_091236.xml · derivative · entry 4

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,600 shares

Expires 2029-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
December 08, 2025 Filed Dec 10, 2025 21:32 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 6,475 $48.66 $315,084.51
Disclosure

SEC source: 0001746251-25-000004 · form4-12102025_091236.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,613

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.215 to $49.08, inclusive.

Read SEC document
December 08, 2025 Filed Dec 10, 2025 21:32 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 11,125 $47.89 $532,770.69
Disclosure

SEC source: 0001746251-25-000004 · form4-12102025_091236.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,088

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.212 to $48.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
December 08, 2025 Filed Dec 10, 2025 21:32 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 17,600 $15.90 $279,840.00
Disclosure

SEC source: 0001746251-25-000004 · form4-12102025_091236.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,213

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.

Read SEC document
August 18, 2025 Filed Aug 20, 2025 20:57 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 16,389 $0.00 Strike: $21.34 $0.00
Disclosure

SEC source: 0001062993-25-014766 · form4.xml · derivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,389 shares

Expires 2030-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
August 18, 2025 Filed Aug 20, 2025 20:57 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 16,389 $38.21 $626,171.25
Disclosure

SEC source: 0001062993-25-014766 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,613

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 18, 2025 Filed Aug 20, 2025 20:57 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 16,389 $21.34 $349,741.26
Disclosure

SEC source: 0001062993-25-014766 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,002

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

Read SEC document
August 13, 2025 Filed Aug 15, 2025 21:08 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 4,861 $0.00 Strike: $21.34 $0.00
Disclosure

SEC source: 0001062993-25-014526 · form4.xml · derivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,389

Underlying: Common Stock · 4,861 shares

Expires 2030-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
August 13, 2025 Filed Aug 15, 2025 21:08 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 4,861 $38.03 $184,880.84
Disclosure

SEC source: 0001062993-25-014526 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,613

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 13, 2025 Filed Aug 15, 2025 21:08 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 4,861 $21.34 $103,733.74
Disclosure

SEC source: 0001062993-25-014526 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

Read SEC document
March 21, 2025 Filed Mar 24, 2025 21:05 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 18,881 $30.03 $566,983.21
Disclosure

SEC source: 0001062993-25-006148 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,613

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.48, inclusive.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:05 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 1,927 $30.00 $57,810.96
Disclosure

SEC source: 0001062993-25-006148 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,494

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 21:34 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 2,255 $30.00 $67,661.05
Disclosure

SEC source: 0001062993-25-005752 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,421

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

Read SEC document
March 11, 2025 Filed Mar 18, 2025 23:18 UTC Amendment COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 15,387 $30.00 $461,671.55
Disclosure

SEC source: 0001062993-25-005834 · form4a.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,676

F1 · date: The original Form 4 filed on March 13, 2025 on behalf of the Reporting Person inadvertently reported the incorrect transaction date. As reported in this amendment, the correct transaction date is March 11, 2025.

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.

Read SEC document
March 07, 2025 Filed Mar 10, 2025 20:01 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 2,348 $30.00 $70,445.87
Disclosure

SEC source: 0001062993-25-005020 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,063

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive.

Read SEC document
March 06, 2025 Filed Mar 10, 2025 20:01 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 3,295 $30.00 $98,853.62
Disclosure

SEC source: 0001062993-25-005020 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,411

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
March 06, 2025 Filed Mar 13, 2025 20:50 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 15,387 $30.00 $461,671.55
Disclosure

SEC source: 0001062993-25-005396 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,676

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 21,670 $30.52 $661,368.40
Disclosure

SEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 4

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,706

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 7,953 $30.52 $242,725.56
Disclosure

SEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,376

F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 26,411 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,329

F2 · shares: Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 26,411 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 45,016 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,918

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
May 24, 2024 Filed May 28, 2024 20:22 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 23,791 $0.00 Strike: $24.03 $0.00
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · derivative · entry 6

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,791 shares

Expires 2028-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
May 24, 2024 Filed May 28, 2024 20:22 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 56,807 $33.98 $1,930,455.24
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 4

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,902

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.68 to $34.25, inclusive.

Read SEC document
May 24, 2024 Filed May 28, 2024 20:22 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 23,791 $24.03 $571,697.73
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 23, 2024 Filed May 28, 2024 20:22 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 51,209 $0.00 Strike: $24.03 $0.00
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · derivative · entry 5

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,791

Underlying: Common Stock · 51,209 shares

Expires 2028-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
May 23, 2024 Filed May 28, 2024 20:22 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 51,209 $33.82 $1,732,093.22
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,918

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.36 to $34.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

Read SEC document
May 23, 2024 Filed May 28, 2024 20:22 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 51,209 $24.03 $1,230,552.27
Disclosure

SEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 21:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 664 $37.15 $24,669.59
Disclosure

SEC source: 0001062993-24-004754 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,918

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.01 to $37.50, inclusive.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 21:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 9,336 $36.38 $339,600.73
Disclosure

SEC source: 0001062993-24-004754 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,582

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.96 to $36.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 21:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 10,145 $33.70 $341,886.50
Disclosure

SEC source: 0001062993-24-003169 · form4.xml · nonDerivative · entry 4

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,918

F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 21:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 19,545 $33.70 $658,666.50
Disclosure

SEC source: 0001062993-24-003169 · form4.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,063

F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 21:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 32,286 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-003169 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,608

F2 · shares: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,286 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Read SEC document
February 12, 2024 Filed Feb 14, 2024 21:14 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 35,000 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-003169 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,322

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Read SEC document
January 16, 2024 Filed Jan 18, 2024 21:19 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 23,560 $32.28 $760,519.16
Disclosure

SEC source: 0001062993-24-001028 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,322

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.01 to $32.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:08 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 13,324 $26.70 $355,750.80
Disclosure

SEC source: 0001062993-23-005854 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,882

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2022.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.22 to $27.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2).

Read SEC document
February 10, 2023 Filed Feb 14, 2023 22:15 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 6,797 $26.75 $181,819.75
Disclosure

SEC source: 0001062993-23-003474 · form4.xml · nonDerivative · entry 4

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,206

F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 22:15 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 14,529 $26.75 $388,650.75
Disclosure

SEC source: 0001062993-23-003474 · form4.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,003

F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 22:15 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 22,459 Not disclosed Not disclosed
Disclosure

SEC source: 0001062993-23-003474 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,532

F2 · price: Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 22,459 performance share units granted in the issuer's three prior fiscal years.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 22:15 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 44,275 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-003474 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,073

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.

Read SEC document
January 09, 2023 Filed Jan 11, 2023 21:06 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 69 $28.58 $1,972.02
Disclosure

SEC source: 0001062993-23-000826 · form4.xml · nonDerivative · entry 3

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,798

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2022.

Read SEC document
January 09, 2023 Filed Jan 11, 2023 21:06 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 7,341 $27.83 $204,300.03
Disclosure

SEC source: 0001062993-23-000826 · form4.xml · nonDerivative · entry 2

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,867

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2022.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.49 to $28.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3).

Read SEC document
January 09, 2023 Filed Jan 11, 2023 21:06 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 10,424 $27.08 $282,281.92
Disclosure

SEC source: 0001062993-23-000826 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,208

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2022.

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.49 to $27.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2).

Read SEC document
July 11, 2022 Filed Jul 13, 2022 20:50 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Tax withholdingCommon Stock 594 $17.48 $10,383.12
Disclosure

SEC source: 0001062993-22-016312 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,632

F1 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 18, 2022 Filed Feb 28, 2022 21:24 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 10,559 $21.61 $228,179.99
Disclosure

SEC source: 0001062993-22-005911 · form4.xml · nonDerivative · entry 1

Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,226

F1 · date: This Form 4 is being filed late due to an administrative error.

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2021 and amended on September 1, 2021.

F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.22 to $21.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.